Company Filing History:
Years Active: 2014
Title: Norihiro Hayashi: Innovator in Prostate Cancer Therapeutics
Introduction: Norihiro Hayashi is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of cancer research, particularly in the development of therapeutics for prostate cancer. His innovative work focuses on targeting specific biological pathways to improve treatment outcomes for patients.
Latest Patents: Hayashi holds a patent for "Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses." This patent outlines methods, uses, and pharmaceutical compositions for the treatment of prostate cancer using a SEMA3C inhibitor. The invention is designed to provide a biologically effective amount sufficient to induce cell death in prostate cancer cells or inhibit their proliferation. The patent specifically addresses androgen receptor (AR) positive prostate cancer and includes various forms of SEMA3C inhibitors, such as antibodies, peptides, antisense RNA, siRNA, shRNA, or small molecules.
Career Highlights: Hayashi is affiliated with the University of British Columbia, where he conducts research and collaborates with other experts in the field. His work has garnered attention for its potential to transform prostate cancer treatment and improve patient outcomes.
Collaborations: Some of his notable coworkers include Christopher J Ong and Martin E Gleave, who contribute to the research efforts in the area of cancer therapeutics.
Conclusion: Norihiro Hayashi's innovative work in developing SEMA3C inhibitors represents a significant advancement in prostate cancer treatment. His contributions to the field highlight the importance of targeted therapies in improving patient care and outcomes.